Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of PF-06818883
NCT03020784Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Nov 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in intracerebral hemorrhage (ICH) comparing Placebo with PF-06818883 (2 arms). Primary endpoints: Change in Number of Participants with Adverse Events as a Measure of Safety and Tolerability at Day 3, Change in Physical examination at Day 3 and 4 more. Started Nov 2016; status: terminated.
02
Drugs
PF-06818883
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT03020784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03020784.